New PET scan method could improve prostate cancer treatment monitoring
NCT ID NCT04158245
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This study tested whether a special PET scan (18F-fluciclovine) can better show how prostate cancer responds to common treatments like abiraterone, enzalutamide, or docetaxel. Nine men with advanced prostate cancer that no longer responds to hormone therapy received one of these treatments. The PET scan was done before and 12 weeks after starting treatment to see if it could detect changes in the cancer better than standard CT or bone scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tulane Cancer Center Clinic
New Orleans, Louisiana, 70112, United States
Conditions
Explore the condition pages connected to this study.